Robo Global Robotics&Automation ETF (ROBO) Reaches $41.39 Formed H&S; 2 Bullish Analysts Covering CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 6 analyst reports since October 29, 2015 according to SRatingsIntel. The rating was initiated by Maxim Group with “Buy” on Thursday, September 22. H.C. Wainwright maintained the shares of CASI in report on Wednesday, April 4 with “Buy” rating. The firm earned “Buy” rating on Monday, August 14 by Maxim Group. The firm has “Buy” rating given on Tuesday, January 16 by H.C. Wainwright. H.C. Wainwright initiated CASI Pharmaceuticals, Inc. (NASDAQ:CASI) on Thursday, October 29 with “Buy” rating. See CASI Pharmaceuticals, Inc. (NASDAQ:CASI) latest ratings:

04/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
16/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain

Robo Global Robotics&Automation ETF (ROBO) formed H&S with $38.49 target or 7.00% below today’s $41.39 share price. Robo Global Robotics&Automation ETF (ROBO) has $2.33B valuation. The ETF increased 2.25% or $0.91 during the last trading session, reaching $41.39. About 644,078 shares traded. Robo Global Robotics&Automation ETF (NASDAQ:ROBO) has risen 29.63% since April 11, 2017 and is uptrending. It has outperformed by 18.08% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $506.52 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Investors sentiment increased to 1.9 in 2017 Q4. Its up 0.76, from 1.14 in 2017Q3. It improved, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 7 reduced holdings. 11 funds opened positions while 8 raised stakes. 3.56 million shares or 48.97% more from 2.39 million shares in 2017Q3 were reported. Virtu Financial Lc holds 12,124 shares. Susquehanna Ltd Liability Partnership holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 24,541 shares. Manufacturers Life Insur The invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields Mgmt Ltd Liability Company invested 0.37% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Northern Trust has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Price T Rowe Associate Md has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 50,400 shares. Royal National Bank Of Canada owns 17,649 shares. Perceptive Limited Liability Co owns 83,682 shares or 0.01% of their US portfolio. Vanguard has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wells Fargo Company Mn owns 50 shares. Renaissance Technologies Ltd Com invested in 150,600 shares. Barclays Public Ltd Liability Co owns 66,720 shares or 0% of their US portfolio. Jpmorgan Chase holds 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 9 shares. Geode Cap Management Ltd Llc accumulated 225,578 shares or 0% of the stock. Goldman Sachs Group Inc has invested 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI).

The stock decreased 2.60% or $0.17 during the last trading session, reaching $6.36. About 1.95 million shares traded or 261.37% up from the average. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 181.56% since April 11, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.